For example, EDITION 1 was a multicentre, open-label, parallel-group study of patients with T2DM receiving current basal therapy with either insulin glargine 100 U/mL or NPH insulin, together with mealtime insulins [16]. The gene discussed is INS; the disease is type 2 diabetes mellitus.